Literature DB >> 7683467

Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors.

C S Killian1, D A Corral, E Kawinski, R I Constantine.   

Abstract

During studies of mitogens in prostate, PSA quantities as low as 2.5 ng/mL caused cultured osteoblast cells to proliferate beyond controls (p = 0.05). Investigation of this novel mitogenicity suggested the use of several mechanisms by PSA, namely: 1) the activation of latent hTGF-beta in PC-3 conditioned medium, PSA treated conditioned medium stimulated DNA uptake in UMR-106 cells to 78% of acid treated conditioned medium, while DNA incorporation was less than controls with anti-hTGF-beta neutralizing IgG; and 2) the proteolytic modulation of cell surface receptors with temporary contact inhibition, PSA significantly stimulated cell detachment while hTGF-beta enhanced cell attachment of confluent Saos-2 cells above controls. Clinically, these results suggest that PSA may provide a mechanism for both tumor spread and the osteoblastic metastasis so common to prostate cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7683467     DOI: 10.1006/bbrc.1993.1506

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  23 in total

Review 1.  New insights into the functional mechanisms and clinical applications of the kallikrein-related peptidase family.

Authors:  Nashmil Emami; Eleftherios P Diamandis
Journal:  Mol Oncol       Date:  2007-09-15       Impact factor: 6.603

2.  PSA-alpha-2-macroglobulin complex is enzymatically active in the serum of patients with advanced prostate cancer and can degrade circulating peptide hormones.

Authors:  Maya B Kostova; William Nathaniel Brennen; David Lopez; Lizamma Anthony; Hao Wang; Elizabeth Platz; Samuel R Denmeade
Journal:  Prostate       Date:  2018-04-16       Impact factor: 4.104

3.  Trypsin-like proteolytic contamination of commercially available psa purified from human seminal fluid.

Authors:  Michael L Manning; Maya Kostova; Simon A Williams; Samuel R Denmeade
Journal:  Prostate       Date:  2011-12-28       Impact factor: 4.104

4.  Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue.

Authors:  H Yu; E P Diamandis; M Levesque; M Giai; R Roagna; R Ponzone; P Sismondi; M Monne; C M Croce
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

5.  Differential distribution of soluble and complexed forms of prostate-specific antigen in cyst fluids of women with gross cystic breast disease.

Authors:  M Malatesta; F Mannello; M Sebastiani; G Gazzanelli
Journal:  J Clin Lab Anal       Date:  2001       Impact factor: 2.352

6.  Homing of cancer cells to the bone.

Authors:  Anjali Mishra; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Cancer Microenviron       Date:  2011-08-09

7.  Kallikrein-related peptidase 12 hydrolyzes matricellular proteins of the CCN family and modifies interactions of CCN1 and CCN5 with growth factors.

Authors:  Audrey Guillon-Munos; Katerina Oikonomopoulou; Noémie Michel; Chistopher R Smith; Agnès Petit-Courty; Sylvie Canepa; Pascale Reverdiau; Nathalie Heuzé-Vourc'h; Eleftherios P Diamandis; Yves Courty
Journal:  J Biol Chem       Date:  2011-05-31       Impact factor: 5.157

8.  Serum total PSA and free PSA in breast tumors.

Authors:  Prakruti Dash; Sanghamitra Pati; Manaswini Mangaraj; Pratima Kumari Sahu; Prakash Chandra Mohapatra
Journal:  Indian J Clin Biochem       Date:  2011-02-04

9.  Molecular insights into substrate specificity of prostate specific antigen through structural modeling.

Authors:  Pratap Singh; Aaron M LeBeau; Hans Lilja; Samuel R Denmeade; John T Isaacs
Journal:  Proteins       Date:  2009-12

10.  Occurrence and localization of uroguanylin in the aging human prostate.

Authors:  Caroline Maake; Franziska Auf der Maur; Katarina Jovanovic; Manfred Reinecke; Dieter Hauri; Hubert John
Journal:  Histochem Cell Biol       Date:  2002-12-21       Impact factor: 4.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.